Heart valve disease is increasingly recognized as a condition with significant immunological underpinnings. This research article explores the role of inflammation and fibrosis in the pathogenesis of heart valve disease. We review the mechanisms by which immune responses contribute to valve dysfunction, the progression from inflammation to fibrosis, and the potential for targeted immunological therapies. Insights from recent studies and clinical trials are discussed to highlight the impact of these mechanisms on disease management and patient outcomes.